Retatrutide: Progress & Potential in Research Models
Summary of Phase 2 findings—weight reduction and liver fat efficacy. For research-use only, not clinical or veterinary.
Key Phase 2 Findings
In a placebo-controlled Phase 2 study of adults with obesity, Retatrutide (at 48 weeks) demonstrated dose-dependent weight loss:
−8.7% at 1 mg; −17.1% at 4 mg; −22.8% at 8 mg; and −24.2% at 12 mg. In comparison, the placebo group saw only a −2.1% change. The 12 mg dose notably achieved ≥15% weight loss in approximately 83% of participants. (ScienceDirect, PubMed)
Liver Fat Reduction in MASLD
In participants with metabolic dysfunction-associated steatotic liver disease (MASLD), 24-week treatment with Retatrutide produced liver fat reductions ranging from approximately −43% to −82%, depending on dosage. By 48 weeks, reductions were even more pronounced (up to −86%), with 86% of subjects achieving normalized liver fat (<5%). (Nature Medicine)
View Retatrutide 22 mg
Research Notes
- The 12 mg dose produced remarkable weight loss nearing −24%, with a high proportion achieving ≥15% loss.
- Favorable reductions in liver fat among MASLD patients suggest broad metabolic effects.
- Reported side effects were mostly gastrointestinal and increased with dosage.
- Results are Phase 2 data—Phase 3 studies are needed to confirm safety and efficacy.
Sources
- Jastreboff AM, et al. Triple-Agonist Retatrutide produces 24% weight loss in obesity phase 2. NEJM. 2023;389(17):1628–1639. (PubMed)
- Sanyal AJ, et al. Retatrutide significantly reduces liver fat in MASLD subjects—up to 86% by 48 weeks. Nat Med. 2024. (Nature Medicine)